Patients who use insulin frequently experience a substantial amount of glycemic variability. On any given day, insulin users can experience extreme high glucose and extreme low glucose levels. Even if the variations aren’t extreme, the ups and downs and the wide variations in glucose levels take their toll on the lives of patients, often impacting mood, the ability to function, think clearly and exercise regularly.
The current “gold standard” for measuring diabetes control, Hb A1C, does not reflect the glycemic variability that impacts the ability of patients to live a healthy, functioning life. Patients need a better measure, which more accurately reflects the impact of glycemic changes on their ability to function and their quality of life.
In recent years, new drugs developed to treat type 2 diabetes have been found to help some type 1 diabetes patients maintain their glucose levels with fewer extreme highs or significant variations. This study will assess the impact of these newer drugs, specifically GLP-1 Analogs and Incretin Mimetics, to help decrease the amount of glycemic variability experienced by patients.
The study will use the methodology developed in the companion study being refined on VitalCrowd “Glycemic Variability Methodology”.